These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 4042523)

  • 1. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations.
    Nakamura K; Goto F; Ray WA; McAllister CB; Jacqz E; Wilkinson GR; Branch RA
    Clin Pharmacol Ther; 1985 Oct; 38(4):402-8. PubMed ID: 4042523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism.
    Wedlund PJ; Aslanian WS; McAllister CB; Wilkinson GR; Branch RA
    Clin Pharmacol Ther; 1984 Dec; 36(6):773-80. PubMed ID: 6499356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin.
    Bertilsson L; Lou YQ; Du YL; Liu Y; Kuang TY; Liao XM; Wang KY; Reviriego J; Iselius L; Sjöqvist F
    Clin Pharmacol Ther; 1992 Apr; 51(4):388-97. PubMed ID: 1345344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of ketoconazole on the polymorphic 4-hydroxylations of S-mephenytoin and debrisoquine.
    Atiba JO; Blaschke TF; Wilkinson GR
    Br J Clin Pharmacol; 1989 Aug; 28(2):161-5. PubMed ID: 2775621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diazepam treatment does not influence the debrisoquine or mephenytoin hydroxylation phenotyping tests.
    Spina E; Buemi AL; Sanz E; Bertilsson L
    Ther Drug Monit; 1989 Nov; 11(6):721-3. PubMed ID: 2595755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype.
    Bertilsson L; Henthorn TK; Sanz E; Tybring G; Säwe J; Villén T
    Clin Pharmacol Ther; 1989 Apr; 45(4):348-55. PubMed ID: 2495208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymorphic debrisoquine and mephenytoin hydroxylation in patients with pulmonary hypertension of vascular origin after aminorex fumarate.
    Saner H; Gurtner HP; Preisig R; Küpfer A
    Eur J Clin Pharmacol; 1986; 31(4):437-42. PubMed ID: 3816924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Debrisoquin and S-mephenytoin hydroxylation phenotypes and CYP2D6 genotypes in an Estonian population.
    Marandi T; Dahl ML; Kiivet RA; Rägo L; Sjöqvist F
    Pharmacol Toxicol; 1996 May; 78(5):303-7. PubMed ID: 8737964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amitriptyline pharmacokinetics and clinical response: II. Metabolic polymorphism assessed by hydroxylation of debrisoquine and mephenytoin.
    Baumann P; Jonzier-Perey M; Koeb L; Küpfer A; Tinguely D; Schöpf J
    Int Clin Psychopharmacol; 1986 Apr; 1(2):102-12. PubMed ID: 3571939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Debrisoquin hydroxylation polymorphism among Ghanaians and Caucasians.
    Woolhouse NM; Andoh B; Mahgoub A; Sloan TP; Idle JR; Smith RL
    Clin Pharmacol Ther; 1979 Nov; 26(5):584-91. PubMed ID: 498701
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Scleroderma is associated with differences in individual routes of drug metabolism: a study with dapsone, debrisoquin, and mephenytoin.
    May DG; Black CM; Olsen NJ; Csuka ME; Tanner SB; Bellino L; Porter JA; Wilkinson GR; Branch RA
    Clin Pharmacol Ther; 1990 Sep; 48(3):286-95. PubMed ID: 2401127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin.
    Sanz EJ; Villén T; Alm C; Bertilsson L
    Clin Pharmacol Ther; 1989 May; 45(5):495-9. PubMed ID: 2721104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man.
    Küpfer A; Preisig R
    Eur J Clin Pharmacol; 1984; 26(6):753-9. PubMed ID: 6489416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. d-Propoxyphene is a potent inhibitor of debrisoquine, but not S-mephenytoin 4-hydroxylation in vivo.
    Sanz EJ; Bertilsson L
    Ther Drug Monit; 1990 May; 12(3):297-9. PubMed ID: 2349617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polymorphism of debrisoquine and mephenytoin hydroxylation among Estonians.
    Kiivet RA; Svensson JO; Bertilsson L; Sjöqvist F
    Pharmacol Toxicol; 1993 Feb; 72(2):113-5. PubMed ID: 8474964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic polymorphism of mephenytoin p(4')-hydroxylation: difference between Orientals and Caucasians.
    Jurima M; Inaba T; Kadar D; Kalow W
    Br J Clin Pharmacol; 1985 Apr; 19(4):483-7. PubMed ID: 3994895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stereoselective disposition of mianserin is related to debrisoquin hydroxylation polymorphism.
    Dahl ML; Tybring G; Elwin CE; Alm C; Andreasson K; Gyllenpalm M; Bertilsson L
    Clin Pharmacol Ther; 1994 Aug; 56(2):176-83. PubMed ID: 8062494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic polymorphism of mephenytoin metabolism.
    Inaba T
    Prog Clin Biol Res; 1986; 214():139-56. PubMed ID: 3523505
    [No Abstract]   [Full Text] [Related]  

  • 19. S-mephenytoin 4-hydroxylase is inherited as an autosomal-recessive trait in Japanese families.
    Ward SA; Goto F; Nakamura K; Jacqz E; Wilkinson GR; Branch RA
    Clin Pharmacol Ther; 1987 Jul; 42(1):96-9. PubMed ID: 3595072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polymorphic metabolism of mephenytoin in man: pharmacokinetic interaction with a co-regulated substrate, mephobarbital.
    Jacqz E; Hall SD; Branch RA; Wilkinson GR
    Clin Pharmacol Ther; 1986 Jun; 39(6):646-53. PubMed ID: 3709029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.